Market
Story
Pfizer's Ibrance Extends Survival by 15 Months in Breast Cancer Patients
Dec 12, 2024, 03:07 PM
Pfizer Inc. has announced that its drug Ibrance, which generates annual sales of $4.3 billion, has shown efficacy in extending median progression-free survival by over 15 months in a Phase 3 study for patients with HR+, HER2+ metastatic breast cancer. This development could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis. The study, known as PATINA, involved combining Ibrance with standard-of-care therapies, marking a potential expansion of its use to a new patient population that represents 10% of breast cancer cases.
View original story
Similar markets
60 to 90 countries • 25%
More than 90 countries • 25%
30 to 60 countries • 25%
Fewer than 30 countries • 25%
European Union • 25%
United States • 25%
Other • 25%
China • 25%
None • 25%
More than two • 25%
Two • 25%
One • 25%
40% to 60% • 25%
20% to 40% • 25%
Less than 20% • 25%
More than 60% • 25%
United Kingdom • 25%
European Union • 25%
Other • 25%
Australia • 25%
Kisqali (ribociclib) • 25%
Verzenio (abemaciclib) • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
European Union • 25%
Other • 25%
Japan • 25%
United States • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Less than 20% • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
United States • 25%
Other • 25%
China • 25%
European Union • 25%